Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Minimum Effective Concentration of Bupivacaine for Motor-Sparing Femoral Nerve Block
NCT02909257Phase 4Terminated
- Sponsor
- Universidad de Chile
- Start
- Sep 2016
- Primary completion
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of bupivacaine in osteoarthritis (OA) and knee injury (2 arms), sponsored by Universidad de Chile. Primary endpoint: Minimum Bupivacaine Analgesic concentration preserving quadriceps strength analgesia at 5 months. Started Sep 2016; status: terminated.
02
Drugs
bupivacaine
03
Conditions
osteoarthritis (OA)knee injury
Beyond the preview
Go deeper on NCT02909257.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02909257.